Loading...
Loading...
Browse all stories on DeepNewz
VisitEli Lilly's Zepbound Achieves 47% Greater Weight Loss Than Novo Nordisk's Wegovy in Phase 3B Trial
Dec 4, 2024, 11:52 AM
Eli Lilly & Co. has reported that its weight-loss drug Zepbound, also known as tirzepatide, outperformed Novo Nordisk A/S's Wegovy, or semaglutide, in a Phase 3B head-to-head clinical trial. The trial showed that Zepbound led to an average weight loss of 20.2% over 72 weeks, compared to 13.7% for Wegovy. Participants using Zepbound lost 50.3 lbs (22.8 kg), while those on Wegovy lost 33.1 lbs (15.0 kg). This 47% greater relative weight reduction has been highlighted by Eli Lilly as a significant achievement in the treatment of obesity. The results have led to a rise in Eli Lilly's stock price, reflecting investor confidence in the drug's potential.
View original story
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Eli Lilly > 60% • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%